Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses

Toxicological Sciences

Volumn 127, Issue 1, 2012, Pages 139-149

  Muenyi, Clarisse S ^a   Pinhas, Allan R ^b,c   Fan, Teresa W ^a,c   Brock, Guy N ^c   Helm, C William ^d   States, J Christopher ^a,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Hyperthermia; Ovarian cancer; P53; Sodium arsenite; XPC

Indexed keywords

ARSENITE SODIUM; CISPLATIN; PLATINUM; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84860189434     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs085     Document Type: Article

References (41)

1. Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., and Perez, J. M. (2007). Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem. 7, 3-18.
2. Chun, Y. J., Park, I. C., Park, M. J., Woo, S. H., Hong, S. I., Chung, H. Y., Kim, T. H., Lee, Y. S., Rhee, C. H., and Lee, S. J. (2002). Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett. 519, 195-200.
3. Cohen, M. H., Hirschfeld, S., Flamm Honig, S., Ibrahim, A., Johnson, J. R., O'Leary, J. J., White, R. M., Williams, G. A., and Pazdur, R. (2001). Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6, 4-11.
4. Cui, X., Kobayashi, Y., Akashi, M., and Okayasu, R. (2008). Metabolism and the paradoxical effects of arsenic: Carcinogenesis and anticancer. Curr. Med. Chem. 15, 2293-2304.
5. Dovern, E., de Hingh, I. H., Verwaal, V. J., van Driel, W. J., and Nienhuijs, S. W. (2010). Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. Eur. J. Gynaecol. Oncol. 31, 256-261.
6. Earley, J. N., and Turchi, J. J. (2011). Interrogation of nucleotide excision repair capacity: Impact on platinum-based cancer therapy. Antioxid. Redox Signal. 14, 2465-2477.
7. Efeyan, A., and Serrano, M. (2007). p53: Guardian of the genome and policeman of the oncogenes. Cell Cycle 6, 1006-1010.
8. Ford, J. M. (2005). Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutat. Res. 577, 195-202.
9. Griffin, R. J., Monzen, H., Williams, B. W., Park, H., Lee, S. H., and Song, C. W. (2003). Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int. J. Hyperthermia 19, 575-589.
10. Hagopian, G. S., Mills, G. B., Khokhar, A. R., Bast, R. C., Jr, and Siddik, Z. H. (1999). Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin. Cancer Res. 5, 655-663.
11. Havrilesky, L. J., Elbendary, A., Hurteau, J. A., Whitaker, R. S., Rodriguez, G. C., and Berchuck, A. (1995). Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol. 85, 1007-1010.
12. Helm, C. W., Bristow, R. E., Kusamura, S., Baratti, D., and Deraco, M. (2008). Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J. Surg. Oncol. 98, 283-290.
13. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
14. Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., and Hamilton, T. C. (1997). Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57, 850-856.
15. Jones, J. C., Zhen, W. P., Reed, E., Parker, R. J., Sancar, A., and Bohr, V. A. (1991). Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem. 266, 7101-7107.
16. Komissarova, E. V., and Rossman, T. G. (2010). Arsenite-induced poly(ADPribosyl) ation of tumor suppressor P53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure. Toxicol. Appl. Pharmacol. 243, 399-404.
17. Kong, B., Huang, S., Wang, W., Ma, D., Qu, X., Jiang, J., Yang, X., Zhang, Y., Wang, B., Cui, B., et al. (2005). Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int. J. Gynecol. Cancer 15, 872-877.
18. Leslie, E. M., Haimeur, A., and Waalkes, M. P. (2004). Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279, 32700-32708.
19. Lin, P. S., McPherson, L. A., Chen, A. Y., Sage, J., and Ford, J. M. (2009). The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. DNA Repair (Amst.) 8, 795-802.
20. Liu, S. Y., Wen, C. Y., Lee, Y. J., and Lee, T. C. (2010). XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage. Toxicol. Sci. 116, 183-193.
21. Maeda, H., Hori, S., Nishitoh, H., Ichijo, H., Ogawa, O., Kakehi, Y., and Kakizuka, A. (2001). Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 61, 5432-5440.
22. Martin, L. P., Hamilton, T. C., and Schilder, R. J. (2008). Platinum resistance: The role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295.
23. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6.
24. Muenyi, C. S., States, V. A., Masters, J. H., Fan, T. W., Helm, C. W., and States, J. C. (2011). Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J. Ovarian. Res. 4, 9.
25. Murgo, A. J. (2001). Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6(Suppl. 2), 22-28.
26. Nakagawa, Y., Akao, Y., Morikawa, H., Hirata, I., Katsu, K., Naoe, T., Ohishi, N., and Yagi, K. (2002). Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci. 70, 2253-2269.
27. Nakayama, K., Takebayashi, Y., Nakayama, S., Hata, K., Fujiwaki, R., Fukumoto, M., and Miyazaki, K. (2003). Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett. 192, 227-235.
28. Neher, T.M., Rechkunova, N. I., Lavrik, O. I., and Turchi, J. J. (2010). Photo-crosslinking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct. Biochemistry 49, 669-678.
29. Nollen, M., Ebert, F., Moser, J., Mullenders, L. H., Hartwig, A., and Schwerdtle, T. (2009). Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression. Mol. Nutr. Food Res. 53, 572-582.
30. Okuda, T., Otsuka, J., Sekizawa, A., Saito, H., Makino, R., Kushima, M., Farina, A., Kuwano, Y., and Okai, T. (2003). p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol. Oncol. 88, 318-325.
31. Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., and Hainaut, P. (2002). The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614.
32. Parker, R. J., Eastman, A., Bostick-Bruton, F., and Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87, 772-777.
33. R Development Core Team. (2011). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
34. Schuijer, M., and Berns, E. M. (2003). TP53 and ovarian cancer. Hum. Mutat. 21, 285-291.
35. Stewart, D. J. (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63, 12-31.
36. Tang, F., Liu, G., He, Z., Ma, W. Y., Bode, A. M., and Dong, Z. (2006). Arsenite inhibits p53 phosphorylation, DNA binding activity, and p53 target gene p21 expression in mouse epidermal JB6 cells. Mol. Carcinog. 45, 861-870.
37. Taylor, B. F., McNeely, S. C., Miller, H. L., and States, J. C. (2008). Arseniteinduced mitotic death involves stress response and is independent of tubulin polymerization. Toxicol. Appl. Pharmacol. 230, 235-246.
38. Uslu, R., Sanli, U. A., Sezgin, C., Karabulut, B., Terzioglu, E., Omay, S. B., and Goker, E. (2000). Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 6, 4957-4964.
39. Wang, W., Qin, S. K., Chen, B. A., and Chen, H. Y. (2001). Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J. Gastroenterol. 7, 702-705.
40. Zhang, J., and Wang, B. (2006). Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol. Oncol. 103, 199-206.
41. Zhang, N., Wu, Z. M., McGowan, E., Shi, J., Hong, Z. B., Ding, C. W., Xia, P., and Di, W. (2009). Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: Therapeutic potential for ovarian cancer. Cancer Sci. 100, 2459-2464.